Abstract:A new infective outbreak, sustained by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and defined coronavirus disease 2019 (COVID-19), is now spreading all around the world.[1] The clinical course of this respiratory disease is complicated in up to 15% of infected patients by onset of interstitial pneumonia, evolving toward acute respiratory distress syndrome needing mechanical ventilation or admission to the intensive care unit (ICU), and is also often accompanied by multiorgan failure.[2] Since there is now incontrovertible evidence that laboratory hemostasis provides an essential contribution to decision-making and care of the vast majority of human pathologies,[3] we aimed to explore here whether increased D-dimer values—which are a frequent occurrence in patients with COVID-19[4]—may be associated with disease severity.An electronic search was performed in Medline (PubMed interface), Scopus, and Web of Science, using the keywords "laboratory" and "COVID-19" or "coronavirus 2019" or "2019-nCoV" or "SARS-CoV-2," between 2019 and present time (i.e., March 4, 2020), with no language restriction. The title, abstract, and full text of all documents that could be identified based on these search criteria were analyzed, and those reporting information on the difference of D-dimer values between COVID-19 patients with or without severe disease (i.e., those needing mechanical ventilation, ICU admission, or those who died) were finally included in our analysis. The reference list of each identified document was also examined for identifying additional eligible studies. A pooled analysis was finally performed, with calculation of weighted mean difference (WMD) and 95% confidence interval (CI) of D-dimer values between COVID-19 patients with or without severe disease, using MetaXL software Version 5.3 (EpiGear International Pty Ltd., Sunrise Beach, Australia). Mean and standard deviation were extrapolated from sample size, median, and interquartile range (IQR), according to Hozo et al.[5] The study was performed in accordance with the Declaration of Helsinki and with the term of local legislation.Overall, 80 documents could be initially identified based on our search criteria, 77 of which ought to be excluded after title, abstract, or full text reading; since they were review articles (n = 6), commentaries, or other editorial material (n = 1), they did not deal with COVID-19 disease (n = 62), or did not expressly reported the difference of D-dimer values in COVID-19 patients with or without severe disease (n = 8). One additional study could be identified from the reference list of selected articles and another one was published while the article was under revision so that a total number of five studies could finally be included in our analysis.[6] [7] [8] [9] [10] Four of these five studies reported median and IQR values of D-dimer,[6] [7] [8] [9] while the remaining only showed the proportion of patients with D-dimer values above the locally defined diagnostic cut-off.[9] In the first study, Huang et al reported clinical and laboratory data of 41 patients hospitalized with laboratory-confirmed COVID-19[6] and observed that D-dimer values were nearly fivefold higher in those with severe disease (median: 2.4 mg/L; IQR: 0.6–14.4 mg/L) than in those without (median: 0.5 mg/L; IQR: 0.3–0.8 mg/L; p = 0.004). Tang et al also studied 183 patients with COVID-19[7] and found that D-dimer values were nearly 3.5-fold higher in those with severe disease (median: 2.12 mg/L; IQR: 0.77–5.27 mg/L) than in those without (median: 0.61 mg/L; IQR: 0.35–1.29 mg/L; p < 0.001). In the third study, published by Wang et al and including 138 patients hospitalized for COVID-19,[8] D-dimer values were nearly 2.5-fold higher in patients with severe disease (median: 4.14 mg/L; IQR: 1.91–13.2 mg/L) than in those without (median: 1.66 mg/L; IQR: 1.01–2.85 mg/L; p < 0.001). In the third study, Zhou et al studied 191 patients with COVID-19[9] and found that D-dimer values were nearly ninefold higher in patients who died (median: 5.2 mg/L; IQR: 1.5–21.1 mg/L) than in those who survived (median: 0.6 mg/L; IQR: 0.3–1.0 mg/L; p < 0.001). In the study -Abstract Truncated-

D-dimer assay interference detected by the discrepancy in D-dimer concentrations at different dilutions: a case report

A Rare Case of Falsely Elevated High-Sensitivity Cardiac Troponin T Due to Antibody Interference and a Literature Review

Interfering antibodies may contribute to elevated D-dimer: a case report

D-dimer—An International Assessment of the Quality of Laboratory Testing: Implications for D-dimer Use in the Real World

D-dimer: Role in the hemostasis system and its application in specific clinical settings

D-dimer: old dogmas, new (COVID-19) tricks

D-Dimer: an analyte with increasing application in Covid-19 infection

A Case of False Decrease of Plasma D-Dimer

D-dimer testing: A narrative review

Advances in D-dimer testing: progress in harmonization of clinical assays and innovative detection methods

Venous Thromboembolism and D-dimer In Patients with COVID-19

Variable Performance of D-dimer Testing by Hemostasis Laboratories: The Australasian/Asia-Pacific Experience

D‐dimer testing in clinical practice in the era of COVID‐19

D-dimer level in COVID-19 infection: a systematic review

Abbott D-dimer assay: analytical performance and diagnostic accuracy in management of venous thromboembolism

Associations of D-Dimer on Admission and Clinical Features of COVID-19 Patients: A Systematic Review, Meta-Analysis, and Meta-Regression

Evaluation of variation in D-dimer levels among COVID-19 and bacterial pneumonia: a retrospective analysis

D-dimer as a Potential Biomarker of Severity in Children Confirmed with COVID-19

D-dimer is Associated with Severity of Coronavirus Disease 2019: A Pooled Analysis

D-dimer as an indicator of prognosis in SARS-CoV-2 infection: a systematic review

Prevalence and Outcomes of D-Dimer Elevation in Hospitalized Patients With COVID-19